ProKidney (PROK) News Today $1.51 +0.05 (+3.42%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ProKidney (NASDAQ:PROK) Shares Down 4.8% - Here's What HappenedProKidney (NASDAQ:PROK) Stock Price Down 4.8% - Here's WhyDecember 18 at 5:12 PM | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in ProKidney Corp. (NASDAQ:PROK)Charles Schwab Investment Management Inc. grew its stake in ProKidney Corp. (NASDAQ:PROK - Free Report) by 150.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 749,718 shares of the company's stock afteDecember 17, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Up 5.9% - What's Next?ProKidney (NASDAQ:PROK) Stock Price Up 5.9% - Time to Buy?December 16, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading 8.4% Higher - What's Next?ProKidney (NASDAQ:PROK) Trading 8.4% Higher - Still a Buy?December 6, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading 5.4% Higher - Time to Buy?ProKidney (NASDAQ:PROK) Stock Price Up 5.4% - Here's What HappenedNovember 29, 2024 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Shares Acquired by Suvretta Capital Management LLCSuvretta Capital Management LLC lifted its holdings in ProKidney Corp. (NASDAQ:PROK - Free Report) by 32.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,341,266 shares of the company's stock after purchasing an additional 3,000,000November 29, 2024 | marketbeat.comUS Penny Stocks To Watch: 3 Picks With Market Caps Under $500MNovember 26, 2024 | finance.yahoo.comProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare ConferenceNovember 26, 2024 | globenewswire.comProKidney purchases former Collins Aerospace facility, own HQ for $22.5MNovember 24, 2024 | bizjournals.comProKidney no longer coming to Greensboro, Chamber of Commerce confirmsNovember 21, 2024 | msn.comProKidney: Manufacturing expansion moving to W-S instead of GreensboroNovember 21, 2024 | bizjournals.comProKidney lists Greensboro property for sale, leaving future in city uncertainNovember 19, 2024 | msn.comFuture of development project promising hundreds of job now uncertainNovember 19, 2024 | msn.comProKidney lists building where it planned $458M investment for saleNovember 18, 2024 | bizjournals.comPharma company to expand Broward headquartersNovember 15, 2024 | bizjournals.comProKidney’s Progress in FDA Approval and Financial HealthNovember 13, 2024 | markets.businessinsider.comProKidney’s Future: Balancing Promising FDA Developments with Financial UncertaintiesNovember 13, 2024 | markets.businessinsider.comProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B MeetingNovember 12, 2024 | globenewswire.comTriad's public companies have gained millions in value since electionNovember 12, 2024 | bizjournals.comProKidney (NASDAQ:PROK) Stock, Option ChainNovember 9, 2024 | benzinga.comProKidney: Major Catalyst Is Too Far AwayNovember 7, 2024 | seekingalpha.comProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare ConferenceNovember 5, 2024 | globenewswire.comPower 50 Five to Watch: Bruce Culleton, ProKidneyOctober 23, 2024 | bizjournals.comWe're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn RateOctober 18, 2024 | finance.yahoo.comProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024October 15, 2024 | markets.businessinsider.comProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024October 14, 2024 | globenewswire.comProKidney to Participate in the UBS Virtual Organ Restoration DayOctober 9, 2024 | globenewswire.comProKidney (NASDAQ:PROK) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comJP Morgan Initiates Coverage of ProKidney (PROK) with Neutral RecommendationOctober 1, 2024 | msn.comMaintaining Hold on ProKidney: Balancing Potential Against Need for Further Efficacy DataSeptember 30, 2024 | markets.businessinsider.comProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. started coverage on shares of ProKidney in a research report on Monday. They issued a "neutral" rating for the company.September 30, 2024 | marketbeat.comGlobal Corporate Wellness Market to Surpass ~USD 117 Billion by 2030 | DelveInsightSeptember 23, 2024 | finance.yahoo.comArch Biopartners Inc. (ARCH.V) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comInsider Selling: ProKidney Corp. (NASDAQ:PROK) Insider Sells 16,412 Shares of StockSeptember 21, 2024 | insidertrades.comProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 SharesProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Darin J. Weber sold 16,412 shares of the company's stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $2.50, for a total transaction of $41,030.00. Following the completion of the transaction, the insider now owns 103,480 shares in the company, valued at approximately $258,700. The sale was disclosed in a legal filing with the SEC, which is available through this link.September 20, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Down 6.7%ProKidney (NASDAQ:PROK) Stock Price Down 6.7%September 20, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Down 3.3% ProKidney (NASDAQ:PROK) Shares Down 3.3%September 12, 2024 | marketbeat.comBuy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease TreatmentSeptember 11, 2024 | markets.businessinsider.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.39ProKidney (NASDAQ:PROK) Shares Gap Up to $2.39September 10, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Earns Buy Rating from Analysts at GuggenheimGuggenheim assumed coverage on ProKidney in a research report on Tuesday. They issued a "buy" rating and a $6.00 price objective for the company.September 10, 2024 | marketbeat.comMaintaining Hold on ProKidney Amid Strategic Shifts and Regulatory UncertaintiesSeptember 5, 2024 | markets.businessinsider.comProKidney’s Hold Rating Maintained Amid Financing and Clinical UncertaintiesSeptember 5, 2024 | markets.businessinsider.comProKidney drops Phase III CKD study to focus on US market and save up to $175mSeptember 5, 2024 | finance.yahoo.comProKidney (NASDAQ:PROK) Stock Price Up 6%ProKidney (NASDAQ:PROK) Shares Up 6%September 5, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Gap Down After Analyst DowngradeProKidney (NASDAQ:PROK) Shares Gap Down Following Analyst DowngradeSeptember 4, 2024 | marketbeat.comBank of America Trims ProKidney (NASDAQ:PROK) Target Price to $3.00Bank of America dropped their price target on shares of ProKidney from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Wednesday.September 4, 2024 | marketbeat.comProKidney Reports Strategic Updates To Phase 3 Study Of Rilparencel; To Discontinue PROACT 2 StudySeptember 4, 2024 | markets.businessinsider.comProKidney revises Phase 3 program for lead assetSeptember 3, 2024 | msn.comProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.September 3, 2024 | globenewswire.comProKidney (NASDAQ:PROK) Trading Down 5.9%ProKidney (NASDAQ:PROK) Trading Down 5.9%August 27, 2024 | marketbeat.com Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. PROK Media Mentions By Week PROK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PROK News Sentiment▼0.710.61▲Average Medical News Sentiment PROK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PROK Articles This Week▼32▲PROK Articles Average Week Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CNTA News RXRX News APGE News IBRX News WVE News MIRM News AKRO News TARS News AMPH News IRON News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PROK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
